Multiple Myeloma

Navigating Cilta-Cel Sequencing in Multiple Myeloma: Surbhi Sidana, MD, MBBS

Value-Based Myeloma Care Amid Game-Changing Therapeutic Developments: Matias Sanchez, MD

Optimizing Multiple Myeloma Treatment as Therapy Costs Rise: Matias Sanchez, MD

Outpatient Models Boost Cost-Effectiveness of CAR T and Bispecific Therapy in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

Leveraging MRD Testing to Advance Value-Based Care in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP

Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP

CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA

Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025

Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MD

Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS